Subcutaneous Guselkumab for Crohn’s: Interpreting GRAVITI Carefully- Gastroenterology Feb.26

Introduction

Fully subcutaneous biologic regimens are attractive in Crohn’s disease because they can reduce infusion burden and improve convenience. The GRAVITI trial evaluated a fully subcutaneous induction and maintenance strategy with guselkumab (IL-23p19) and reported improvements in clinical remission and endoscopic response through 48 weeks.

The key questions raised for GRAVITI

1) Does the endoscopic endpoint reliably reflect inflammation (vs fibrosis)?

The coprimary endoscopic endpoint relied on improvement in SES-CD.

The critique highlights a real-world limitation: SES-CD can over-score fibrostenotic segments as “active” disease, potentially inflating perceived response.

This concern is most relevant in ileal-predominant Crohn’s, where fibrostenotic disease is common.

Clinical implication: If fibrotic strictures are misclassified as inflammatory activity, “endoscopic response” may not always mean the drug is reversing active inflammation.

What would strengthen confidence:

histologic correlation (where feasible),

imaging stratification (e.g., MRE features of fibrosis vs inflammation),

or predefined exclusion of fixed fibrotic strictures.

2) Does crossover/rescue design distort placebo vs drug comparisons?

A major critique is that a substantial proportion of placebo patients crossed over to active therapy early and were then counted as “nonresponders” for placebo in longer-term analyses.

Why clinicians should care:

This can make:

placebos look artificially low long-term, and

Active therapy looks stronger by comparison.

What would help:

reporting outcomes for rescued participants as a separate analytic group,

sensitivity analyses that show how rescue impacts the effect size.

3) Is the SC induction dose “validated,” especially in higher-clearance subgroups?

The SC induction regimen appears to have been extrapolated from IV data using assumed bioavailability, rather than derived from dedicated SC dose-ranging.

The critique emphasises that:

Some patients (e.g., higher BMI) may have altered clearance,

and without pharmacokinetic (PK) and exposure–response analyses, it’s hard to know whether the SC dose is optimised.

Clinical implication: In real practice, heterogeneous PK could mean variable efficacy—especially in patients who need rapid disease control.

What would help:

through levels and exposure–response relationships,

subgroup analyses by BMI,

and explicit discussion of underdosing risk vs safety margin.

4) How does SC guselkumab compare with IV induction (the established route)?

Even if SC regimens are convenient, clinicians want to know:

Is SC truly noninferior to IV for induction?

Are there differences in early control, durability, or safety?

The critique argues that cross-trial comparisons are not enough, and head-to-head or noninferiority designs would provide the clarity needed to guide route choice.

Additional pragmatic points raised

Prior IL-23 exposure: With increasing real-world use of IL-23 agents, the key question is whether guselkumab works after prior IL-23p19 therapy (class effect vs meaningful differences).

Durability beyond 48 weeks and “deep remission” outcomes: endoscopic healing, sustained steroid-free remission, and persistence/adherence matter for practice.

Health system implications: SC induction reduces infusion-centre burden but shifts monitoring and adherence responsibility—raising the need for cost-effectiveness and implementation studies.

Bottom-line takeaway:

GRAVITI supports the feasibility of fully subcutaneous guselkumab in Crohn’s disease, but important uncertainties remain about endpoint interpretation (fibrosis vs inflammation), rescue-related bias, PK validation across patient subgroups, and how SC compares directly with IV induction. Clinicians should view the results as promising, not definitive, and await more granular analyses and head-to-head data before changing protocols broadly.

One-line GastroAGI takeaway

SC guselkumab in Crohn’s looks promising—but GRAVITI’s design leaves key unanswered questions about “true” endoscopic benefit and real-world dosing.